Outlook Therapeutics (NASDAQ: OTLK) links CEO and CFO rewards to FDA call
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. approved new equity and cash incentives for its chief executive and chief financial officers tied to potential FDA approval of ONS-5010 (bevacizumab-vikg). The awards recognize their efforts during 2025 and 2026 advancing the Biologics License Application through FDA review and appeal processes.
The chief executive officer received options to purchase 100,000 shares and the chief financial officer 210,078 shares under the 2024 Equity Incentive Plan, all at an exercise price of $1.4304 per share, vesting on July 21, 2027 subject to continued service. They also received cash bonus opportunities of $420,000 and $200,000, respectively, which will be earned and payable only if, on or before July 31, 2026, the FDA approves ONS-5010 and issues a favorable decision on the Biologics License Application and each executive remains in service through payment.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
CEO stock options: 100,000 options
CFO stock options: 210,078 options
Option exercise price: $1.4304 per share
+4 more
7 metrics
CEO stock options
100,000 options
Options to purchase common stock granted July 21, 2026 to the chief executive officer
CFO stock options
210,078 options
Options to purchase common stock granted July 21, 2026 to the chief financial officer
Option exercise price
$1.4304 per share
Exercise price for options granted under the 2024 Equity Incentive Plan
Option vesting date
July 21, 2027
Date on which the granted options vest and become exercisable, subject to continued service
CEO bonus opportunity
$420,000
Cash bonus amount contingent on FDA approval of ONS-5010 by July 31, 2026
CFO bonus opportunity
$200,000
Cash bonus amount contingent on FDA approval of ONS-5010 by July 31, 2026
Bonus condition deadline
July 31, 2026
Latest date by which FDA must approve ONS-5010 for bonuses to be earned
Key Terms
Biologics License Application, bevacizumab-vikg, 2024 Equity Incentive Plan, exercise price
4 terms
Biologics License Application regulatory
"advancing the Company’s Biologics License Application (the “BLA”) for ONS-5010"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
bevacizumab-vikg medical
"the Company’s BLA for ONS-5010 (bevacizumab-vikg) through the review"
Bevacizumab-vikg is a biosimilar version of a cancer-fighting monoclonal antibody that blocks a protein tumors use to grow blood vessels, effectively starving them of nutrients. For investors, it matters because biosimilars offer a lower-cost alternative to an established biologic drug, which can capture market share, compress prices, and change revenue forecasts for companies selling the original drug or competing copies — think of it as a generic equivalent for a complex, high-priced medicine.
2024 Equity Incentive Plan financial
"granted pursuant to the Company’s 2024 Equity Incentive Plan (the “2024 Plan”)"
exercise price financial
"with an exercise price of $1.4304 per share, the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive compensation actions did Outlook Therapeutics (OTLK) take on July 21, 2026?
Outlook Therapeutics approved new stock option grants and conditional cash bonus opportunities for its CEO and CFO. The package includes options on 100,000 and 210,078 shares and potential cash bonuses of $420,000 and $200,000, tied to possible FDA approval of ONS-5010.
What stock options were granted to Outlook Therapeutics (OTLK) executives and at what price?
The CEO received options to purchase 100,000 shares and the CFO 210,078 shares of common stock. All options were granted under the 2024 Equity Incentive Plan with an exercise price of $1.4304 per share and will vest on July 21, 2027, subject to continued service.
What are the cash bonus amounts and conditions for Outlook Therapeutics (OTLK) CEO and CFO?
The CEO was awarded a cash bonus opportunity of $420,000 and the CFO $200,000. Each bonus will be earned and payable only if, on or before July 31, 2026, the FDA approves ONS-5010 and issues a favorable decision on the company’s Biologics License Application, with continued service required.
How is FDA approval of ONS-5010 linked to Outlook Therapeutics (OTLK) executive pay?
Both executives’ cash bonuses are contingent on FDA approval of ONS-5010 (bevacizumab-vikg) and a favorable decision on the Biologics License Application by July 31, 2026. Without this regulatory outcome, the bonuses will not be earned or paid.
When do the new Outlook Therapeutics (OTLK) executive stock options vest?
All option awards granted to the CEO and CFO vest and become exercisable on July 21, 2027. Vesting is subject to each executive’s continued service with Outlook Therapeutics through that date, aligning the incentive with ongoing tenure at the company.